Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Albertsen, B K
Andersson, N G
Bendtsen, M D
Gunnes, M W
Heyman, M M
Jonsson, O G
Trakymiene, S S
MetadataShow full item record
CitationThromb. Haemost. 2016, 14 (3):485-94 J.
ÚtdrátturBackground Thromboembolism (TE) is a major toxicity in children with acute lymphoblastic leukemia (ALL) and may have a negative impact on ALL treatment. Objectives To examine the cumulative incidence, outcomes and risk factors associated with TE in children with leukemia. Patients/Methods We prospectively evaluated TE in 1038 Nordic children and adolescents (≥ 1 and < 18 years) diagnosed with ALL during 2008-2013 and treated according to the NOPHO (Nordic Society of Pediatric Hematology and Oncology)-ALL 2008 protocol. The cohort was followed until December 2014. Cox proportional regression was used to compute hazard ratios (HRs). Results TE events (n = 63) occurred most frequently in conjunction with asparaginase (ASP) administration (52/63). The cumulative incidence of TE was 6.1% (95% confidence interval [CI], 4.8-7.7). Being aged 15-17 years was associated with an increased risk of TE (adjusted HR of 4.0; 95% CI, 2.1-7.7). We found a TE-associated 30-day case fatality of 6.4% (95% CI, 1.8-15.5) and TE-related truncation of ASP therapy in 36.2% (21/58). Major hemorrhage occurred in 3.5% (2/58) of anticoagulated patients. Minor hemorrhage was reported in two out of 58 patients. No major bleeds occurred in children who received low-molecular-weight heparin. Conclusions Methods to identify children and adolescents who will benefit from thromboprophylaxis during ALL treatment are called for. The truncation of ASP should be avoided. The long-term survival outcomes for ALL patients with TE require close monitoring in the future.
Lu00FDsingTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Journal of thrombosis and haemostasis : JTH
- Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
- Authors: Athale UH, Laverdiere C, Nayiager T, Delva YL, Foster G, Thabane L, Chan AK
- Issue date: 2017 May 4
- Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.
- Authors: Ranta S, Tuckuviene R, Mäkipernaa A, Albertsen BK, Frisk T, Tedgård U, Jónsson ÓG, Pruunsild K, Gretenkort Andersson N, Winther Gunnes M, Saulyte Trakymiene S, Frandsen T, Heyman M, Ruud E, Helgestad J
- Issue date: 2015 Feb
- TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
- Authors: Klaassen ILM, Lauw MN, van de Wetering MD, Biemond BJ, Middeldorp S, Abbink FCH, Bierings M, Te Loo DMMW, Pieters R, van der Sluis IM, Tissing WJE, Michel Zwaan C, Heleen van Ommen C
- Issue date: 2017 May 10
- PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
- Authors: Henriksen LT, Harila-Saari A, Ruud E, Abrahamsson J, Pruunsild K, Vaitkeviciene G, Jónsson ÓG, Schmiegelow K, Heyman M, Schrøder H, Albertsen BK, Nordic Society of Paediatric Haematology and Oncology (NOPHO) group.
- Issue date: 2015 Mar
- Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
- Authors: Toksvang LN, De Pietri S, Nielsen SN, Nersting J, Albertsen BK, Wehner PS, Rosthøj S, Lähteenmäki PM, Nilsson D, Nystad TA, Grell K, Frandsen TL, Schmiegelow K
- Issue date: 2017 Sep